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INTRODUCTION:  Insulin  resistance  (IR),  leptin  resistance  (LR),  and  polycystic  ovary  syndrome  (PCOS)  com-
monly coexists  with  obesity.  IR and  PCOS  are  often  successfully  treated  with  the use  of  insulin-sensitizing
drugs  (ISDs).  However,  some  women  are poorly  responsive  or intolerant  to them.  If  we additionally  con-
sider that  currently  no  medical  treatment  for LR  exists,  it is  crucial  for the physician  to ﬁnd  different
therapeutic  ways to  treat patients  with such  multifactorial  endocrinopathy.
PRESENTATION  OF  CASE:  We  present  a case  where  sleeve  gastrectomy  (SG)  was  applied  to  a  27-year-old
obese  woman  affected  by concomitant  IR,  LR and  PCOS,  and  unresponsive  to ISDs.  At three  years  from
surgery  the  patient  is now  71.6  kg.  More  importantly,  her  levels  of  insulin  and  leptin  started  to improve  at
postoperative  month  6  and  became  normal  at postoperative  month  24.  Patient’s  ovaries  that  at  baseline
had  characteristic  aspects  related  to  PCOS,  at postoperative  month  36  were  normal.
DISCUSSION:  SG  is one  of  the most  commonly  performed  bariatric  procedures.  The  literature  has  moved
away  from  labeling  SG  as a purely  restrictive  procedure,  as  its interactions  with  several  hormones  (ghrelin,
leptin,  insulin,  etc.) are  now  recognized.
CONCLUSION:  In  the  present  report,  SG  was  applied  to resolve  an  intricate  endocrinological  framework
conﬁrming  its therapeutic  value  not  only  in  determining  weight  loss  but  also as  endocrine/metabolic
surgery able  to  treat multifactorial  endocrinopathy.  The  underlying  molecular  mechanisms  contributing
to  these  beneﬁts  remain  largely  undetermined,  despite  offering  tremendous  potential  to  reveal  new
targets  for  therapeutic  intervention,  mostly  in those  patients  unresponsive  to classical  pharmacotherapy.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  on behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
Obesity is a complex disease for which no single cause exists.
lthough eating habits, lifestyle, genetics and emotional concerns
re main factors involved in obesity etiopathogenesis, some med-
cal conditions may  also cause weight gain. Insulin resistance (IR),
eptin resistance (LR) and polycystic ovary syndrome (PCOS) com-
only coexist with obesity [1]. PCOS is a common endocrine
isorder affecting 6–21% of women of reproductive age [2], and
bout 50% of PCOS patients are obese [3]. In most cases, PCOS also
nvolves metabolic alterations such as IR, hyperinsulinemia, and
yslipidemia. PCOS can thus lead to increased risk of developing
ype 2 diabetes mellitus and cardiovascular disease in patients [4].
besity is deﬁned by abnormal or excessive lipid storage in the
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adipose tissue cells. Adipose tissue is not only considered the main
energy reservoir but also a pivotal endocrine organ involved in the
regulation of many physiological processes, by secreting a variety
of bioactive cytokines, such as leptin [5]. Leptin is involved in the
regulation of food intake, energy balance, and body weight [5].
Obesity and IR are crucial parameters of PCOS. As leptin is pri-
marily secreted by adipose tissue and also has activity at an ovarian
level, it is interesting to know whether serum leptin levels are cor-
related with IR in PCOS. However, this correlation is still a matter of
debate and further research is required to clarify the relationship
between leptin, IR in PCOS.
While there is currently no medical treatment for LR, IR and
PCOS are often successfully treated with the use of insulin-lowering
agents (ISDs) [6–7]. However, some women are unresponsive to
this type of pharmacotherapy [8].The case of a 27-year-old morbidly obese woman suffering from
concomitant IR, LR, PCOS, and unresponsive to ISDs, treated with
SG is here reported.
up Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Gig. 1. Ovary ultrasound image (a) Baseline. The ovary has many small cysts (2–7 m
onth 36. The ovary appears normal with a dominant (asterisk) follicle present.
. Case presentation
In 2011, a 27-year-old Italian female with a body mass index
BMI) of 49.9 kg/m2 (weight = 141 kg; height = 168 cm)  was referred
or bariatric surgery intervention for obesity. The patient had
nown concomitant IR and LR associated to PCOS since puberty.
atient clinical history was also characterized by unresponsive-
ess to ISDs (metformin, and thiazolidinedione) even at maximum
ose. The patient also reported that she stopped high doses of pre-
cribed pharmacotherapy on several occasions due to side effects
abdominal discomfort, cramping, diarrhoea and nausea).
Despite strict adherence to several exercise-associated diet
rograms, extremely aggressive diets, such as ketogenic enteral
utrition, and drugs for obesity treatment, the patient had con-
inued to gain weight. Over the past two years, her plasma insulin
evels were 21–36 IU/mL (normal range 6–29 IU/mL) and plasma
eptin levels were 89–130 ng/mL (normal range 0.5–12.7 ng/mL).
In 2009, the patient was treated with a 6-month placement
f intragastric balloon. In six months the patient lost 21 kg (from
able 1
atient characteristics at baseline e during the follow-up.
Clinical characteristics Baseline Post-LSG(6 months
Age (years) 27 27 
Height  (cm) 1.68 1.68 
Body  Weight (kg) 141 105.7 
BMI  (kg/m2) 49.9 37.5 
Leptin  (range 0.5–12.7 ng/mL) 123.2 30.8 
Glucose (range 70–110 mg/dL) 164 102 
Insulin  (range 6–29 IU/mL) 29.4 21.3 
Glycated Hemoglobin (range 5–20%) 9.2 6.4 
Homa  index (range 0.23–2.5) 11.9 5.36 
Liver  left lobe size (rage 9–10 cm)  16.3 11.2 
Liver  right lobe size (rage 12–14 cm)  21.2 13.9 
Total  cholesterol (normal value <190 mg/dL) 251 189 
HDL  (normal value >45 mg/dL) 39 44 
LDL  (normal value <100 mg/dL) 154.8 107 
Total  cholesterol/HDL ratio (normal value <4.5) 6.43 4.3 
Triglycerides (normal value <150 mg/dL) 286 190 
GOT  (range 7–45 U/L) 49 24 
GPT  (range 8–43 U/L) 43 21 
GGT  (range 6–29 U/L) 35 25 
Menstrual cycles Amenorrhea Irregular 
oma index = homeostatic model assessment.
DL = high density lipoprotein.
DL = low density lipoprotein.
OT = glutamic oxaloacetic transaminase.
PT = glutamic pyruvic transaminase.
GT = gamma-glutamyl transferase.meter), giving the ovary a characteristic “polycystic” appearance. (b) Postoperative
131 kg to 110 kg) with a concomitant improvement of both IR,
LR, and PCOS indicating, as reported in the literature, weight loss
has a pivotal role in the etiopathogenesis of both IR and LR, and
improved menstrual frequency. Unfortunately, although weight
loss and lifestyle modiﬁcations are the ﬁrst line treatment in PCOS,
IR, and LR, they are associated with low adherence and sustain-
ability over time. Therefore, the patient completely regained this
weight loss three months after the balloon was removed, with a
concomitant deterioration of both IR and LR.
After considering overall clinical history and a careful preopera-
tive multidisciplinary clinical screening, the patient was considered
eligible for obesity surgery. Patient’s clinical characteristics before
surgery (baseline) are reported in Table 1 and Fig. 1a, and clearly
show high levels of hyperinsulinemia, hyperleptinemia, IR (HOMA
index 11.9 vs normal range 0.23–2.5), dyslipidaemia, enlarged liver
associated with high levels of transaminases, PCOS, and amenor-
rhea.
The patient then underwent a laparoscopic sleeve gastrectomy
(LSG) for correction of her obesity. During the operation, there
) Post-LSG(12 months) Post-LSG(24 months) Post-LSG(36 months)
28 29 30
1.70 1.71 1.72
91.4 74.3 69.4
31.6 25.4 23.4
11.3 2.3 1.9
86 79 74
11.5 6.1 2.9
6.1 5.9 5.7
2.44 1.19 0.53
11.6 11.2 11.2
12.8 12.1 13.4
174 161 154
45 51 62
94.6 83.4 67,2
3.9 3.1 2.5
172 133 124
21 23 16
19 17 19
22 19 17
Normal Normal Normal
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ere no intra-operative complications. Post-operative course was
neventful. On day 5, a routine upper gastrointestinal gastrograﬁn
wallow study was performed and showed no evidence of leak or
bstruction. Therefore, she was discharged home in a stable con-
ition. After discharge on the ﬁfth postoperative day, the patient
ssumed a liquid diet that was changed to puree-based after 15
ays, and after four additional weeks, to soft solid food. The patient
as also instructed to regularly follow an enriched protein diet
9], to take daily vitamin supplements, and physical activity was
ncouraged. Obviously, the surgery goals were to decrease total
ody weight and improve lipid and haepatic proﬁle, IR, LR, and con-
equently the PCOS. Patient presence at scheduled follow-up visits
6, 12, 24 and 36 months) was 100%.
Patient’s postoperative clinical characteristics are reported in
able 1 and Fig. 1b. In particular, the patient lost 35.3 kg six months
fter surgery, and 49.6 kg, 66.7 kg and 71.6 kg, at 12, 24 and 36
onths after the surgery, respectively. At postoperative month 36,
MI  was 23.4 kg/m2 that on the basis of BMI  categories is considered
 healthy weight. More importantly, patient levels of insulin and
eptin started to improve at postoperative month 6 to become nor-
al  at postoperative month 24. At postoperative month 36, plasma
nsulin and leptin levels were 2.9 IU/mL and 1.9 ng/mL, respec-
ively, for insulin and leptin range values (Table 1) this is considered
ormal. Furthermore, as shown in Fig. 1, patient’s ovaries that at
aseline (a) had characteristic aspects related to PCOS, at postop-
rative month 36 (b) may  be deﬁned as normal. In fact, the patient
eported that starting from postoperative month 12 her menstrual
ycle became regular with a frequency range of 27–31 days.
. Discussion
The relationship between leptin, IR in PCOS is still a matter of
ebate. Patients become LR by the same mechanism associated
ith IR, through a continuous overexposure to high levels of hor-
one [10–12]. Over time, if the body is exposed to excess leptin,
t will become resistant, just as it can become resistant to insulin.
hile there is currently no medical treatment for LR, IR is often
uccessfully treated with the use of insulin-lowering agents or ISDs.
harmacotherapy is also used in PCOS, including the oral contra-
eptive pill and ISDs. Infact, the recognition of IR as a principal
actor in the pathogenesis of PCOS has led to the use of ISDs for
COS treatment. For instance, troglitazone is a drug that improves
R and hyperinsulinemia without altering leptin levels [13]. By con-
rast, metformin, an insulin sensitizer widely used for treating type
 diabetes mellitus, considerably reduces serum leptin concentra-
ion in obese and non-obese PCOS patients [14]. However, some
omen are unresponsive to this type of pharmacotherapy.
To our knowledge, only one case of a 16-year-old Caucasian male
ith LR and successfully treated with bariatric surgery has been
eported in the medical literature [15]. To our knowledge, this is the
rst report of bariatric surgery in a morbidly obese patient suffering
rom concomitant IR, LR, PCOS, and unresponsive to ISDs. In the
resent case the patient was effectively treated with SG.. Conclusion
Bariatric surgical procedures, such as SG, are currently the most
ffective therapy for the treatment of obesity. In the present report,
[
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SG was  applied to resolve an intricate endocrinological framework
conﬁrming its therapeutic value not only in effectively determining
weight loss but also as endocrine/metabolic surgery able to treat
multifactorial endocrinopathy. The underlying molecular mecha-
nisms contributing to these beneﬁts remain largely undetermined,
despite offering tremendous potential to reveal new targets for
therapeutic intervention, mostly in those patients unresponsive to
classical pharmacotherapy.
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